For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.
People say the world is getting smaller. In some ways, that’s true. Global trade, the Internet, affordable international travel and instant communications have all made access easier. If you’re a biotechnology company today, you’re as likely to sell product in China as in Kentucky. But paradoxically, a smaller world is also a bigger world: greater ease of doing business means more business to do.
Developing countries provide huge opportunities for those who can operate effectively in them, but there are dangers too. And even though one of the symptoms of our shrinking world is that law, rules and regulations are trending towards harmonisation, there is a long way to go before companies can have confidence that they will be treated the same way wherever they operate.
That’s where the Biotechnology Industry Organization (BIO) comes in. Joe Damond, senior vice president of international affairs, is responsible for advancing the interests of the biotech industry around the world.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
BIO, biotechnology, Natco, WIPO